Table 3.
Comparison of resected ASCP to PDAC
| Study | Data source | No. Of patients | Poor diff (%) | Node-positive (%) | Tumor size (cm) | Median OS (mo) | OS (%) | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
| ||||||||||||||
| ASCP | PDAC | ASCP | PDAC | ASCP | PDAC | ASCP | PDAC | ASCP | PDAC | ASCP | PDAC | Time | ||
| [78] | single institution | 91 (2.3%) | 3918 | 79.5 | 35.9 | 88 | 78 | 4.0 | 3.2 | 10.8 | 20.5 | 18.2 | 17.5 | 5y |
| [79] | SEER | 176 (1.0%) | 17411 | 49.4 | 27.2 | 51.4 | 48.4 | 5.3 | 3.9 | 12 | 16 | 29 | 35.8 | 2y |
| [80] | NCDB | 503 (1.4%) | 35492 | 57 | 33 | 55 | 61 | 53%* | 30%* | 14.8 | 22 | 18.2 | 19.2 | 5y |
| [81] | CA Cancer Reg | 31 (1.5%) | 2071 | 57.7 | 60.2 | 4.6 | 3.3 | 12 | NR | |||||
Digits in italics indicate the study found a statistically significant difference in this measure.
*
Indicates measurement of percent tumors ≥ 4 cm. Poor diff: Poorly differentiated tumor on histology; OS: overall survival; NR: not reported.